Loreal 2013 Annual Report Download - page 75

Download and view the complete annual report

Please find page 75 of the 2013 Loreal annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 96

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96

MAJOR ADVANCES FOR PATIENTS
AND HEALTHCARE PROFESSIONALS
Mirvaso®, developed through GALDERMA research, is the first
topical treatment for rosacea-associated erythema.
Approved by the Food and Drug Administration (FDA), the
American regulatory agency, it was launched in the United
States in autumn 2013. Mirvaso® is a major advance for
rosacea patients, and reflects GALDERMA’s commitment to
targeting this disease, which affects millions of people
throughout the world.
The acquisition of Spirig in December 2012 also bolstered
the self-medication product portfolio, which posted solid
growth. The research and production centre at Egerkingen
in Switzerland became a Centre of Excellence for self-
medica tion in 2013, strengthening the laboratory’s exper-
tise and resources in this market.
In aesthetic and corrective dermatology, the complete
portfolio of medical solutions – including Azzalure® (muscle
relaxant) and Restylane® (dermal filler) – is backed up by a
new brand expression and the roll-out of a new programme
of associated services. Its objective? To enable doctors to
be even more attentive to their patients, so as to offer per-
sonalised treatments.
STAYING CONNECTED TO THE DERMATOLOGY
COMMUNITY
In addition to the renewal of its institutional website,
GALDERMA is continuing to actively support continuous
medical training through its platforms for sharing medical
knowledge online, such as www.dermquest.com which
brings together more than 60,000 dermatologists world-
wide(2). GALDERMA also has a mission to inform patients
andraise their awareness, for example with the website
www.rosaceafacts.com dedicated to rosacea.
(1) Source: IMS, class D, 39 countries, MAT November 2013. (2) Source: GALDERMA data.
(3) Source: IMS, MAT November 2013.
Australia,
an emblematic
example
Australia is a fine illustration of the strategy
adopted by GALDERMA: all three activities
have been extensively rolled out, and are
posting solid performances thanks to the
successes of its flagship brands. Epiduo®,
which is reimbursed in Australia, has held on
to its No.1 position there in topical acne
treatments(3). The growth in self-medication
products is being driven in particular by the
launch of Actinica® (prevention of non-mela
- noma skin cancer), supported by the Skin
and Cancer Foundation. The aesthetic and
corrective solutions meanwhile are continu-
ing to record strong growth, driven by
Restylane® and by rising sales of Dysport®
(muscle relaxant).
5
RESEARCH AND DEVELOPMENT CENTRES
EXCLUSIVELY DEDICATED TO DERMATOLOGY
www.dermquest.com
A personalised continuous
medical training platform
for dermatologists.
73